Physician profile
Kristine Rietsma
NPI 1609118389
$1,836.49
in general payments reported to CMS, 2019-2025
26 companies · $273 in 2025
The $273 reported for 2025 was more than what 82% of Pediatrics providers received nationally (typical 2025 total: $96.93).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $396 · 2020: $319 · 2021: $207 · 2022: $113 · 2023: $244 · 2024: $284 · 2025: $273.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $801.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $800.79 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Cranial Technologies, INC | $170.11 | 2019-2025 | Doc Band |
| Pfizer INC. | $168.00 | 2019-2024 | |
| Corium, LLC | $153.46 | 2022-2025 | Azstarys |
| Genentech USA, INC. | $149.18 | 2019-2022 | |
| Merck Sharp & Dohme LLC | $145.11 | 2019-2024 | Vaxneuvance, Gardasil 9, Vaxelis |
| Sanofi Pasteur INC. | $131.29 | 2021-2025 | |
| Takeda Pharmaceuticals U.S.A., INC. | $127.00 | 2020-2021 | |
| Ironshore Pharmaceuticals INC. | $103.62 | 2019-2024 | Jornay Pm |
| Glaxosmithkline, LLC. | $81.71 | 2019-2025 | Bexsero, Pediarix, Rotarix |
| Sanofi-Aventis U.S. LLC | $69.78 | 2024-2025 | |
| Neos Therapeutics, LP | $54.67 | 2019-2020 | |
| Kyowa Kirin, INC. | $53.12 | 2023-2024 | Crysvita |
| Kaleo, INC. | $48.48 | 2019-2020 | |
| Supernus Pharmaceuticals, INC. | $46.30 | 2021-2024 | Qelbree |
| Collegium Pharmaceutical, INC. | $42.05 | 2025 | Jornay Pm |
Show all 26 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Adlon Therapeutics L.P. | $41.87 | 2019-2020 | |
| Tris Pharma INC | $39.61 | 2019 | |
| Verrica Pharmaceuticals INC. | $39.20 | 2025 | Ycanth |
| Rhodes Pharmaceuticals L.P. | $31.40 | 2019 | |
| Alk-Abello, INC | $25.39 | 2023 | Grastek, Odactra, Ragwitek |
| Astrazeneca Pharmaceuticals LP | $21.64 | 2023 | Flumist Quadrivalent |
| Novartis Pharmaceuticals Corporation | $20.80 | 2019 | |
| Shire North American Group INC | $20.46 | 2019 | |
| Aytu Biopharma, INC. | $17.99 | 2020 | |
| Vyne Pharmaceuticals INC. | $17.58 | 2020 | |
| Vertical Pharmaceuticals, LLC | $16.67 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Kristine Rietsma listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.